Q3 2025 Revenue of $21.8 million, an increase of 20% over Q3 2024; Q3 2025 gross profit margin of 81%, a 400-basis point improvement from Q3 2024; Raised FY2025 Total Revenue Guidance to $84-86 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the third quarter ended September 30, 2025. “We delivered a strong third quarte ...

Mdxhealth to Release Third Quarter 2025 Financial Resultson November 12 Company to Host Conference Call with Live Q&A, November 12, 2025, at 4:30pm ET / 22:30 CET IRVINE, California – November 3, 2025 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH), a leading precision diagnostics company, today announced it will release its financial results for the third quarter ended September 30, 2025, after market close on Wednesday, November 12, 2025. Title:Mdxhealth Presents Third Quarter 2025 Financial Results andCorp ...

Guardant Health, Inc. ( GH ) is a cancer genomics diagnostics company. GH leverages the SMART platform, which spans screening, therapy selection, minimal residual disease (MRD), and surveillance across all stages of cancer. GH’s business segments include Oncology as the anchor, Screening, and Biopharma & Data. InMy name is Myriam Hernandez Alvarez. I received the Electronics and Telecommunication Engineering degree from the Escuela Politecnica Nacional, Quito, Ecuador, the M.Sc. degree in computer science f ...

Shares of Guardant Health Inc. (GH) are up over 25% at $90 in premarket trading on Thursday, after the company reported exceptionally strong financial results for the quarter ended September 30, 2025, and raised its full-year 2025 outlook.This commercial-stage precision oncology company Guardant360 Liquid test and Guardant360 CDx test, the first comprehensive liquid biopsy test approved by the FDA to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection w ...

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at pavmed.com. About PAVmedPAVmed Inc. is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors. Its subsidiary, Lucid Diagnostics (Nasdaq: LUCD), is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal ...

Speaker panel will include collaborative case study presentations from strategic partners: Memorial Sloan Kettering Cancer Center, Bio-Rad Laboratories, and Thermo Fisher ScientificLOUISVILLE, Colo., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announces its Corporate and Scientific presentations, and exhibitor presence at the 2025 AMP Annual Meeting, November 12-15, in Boston, MA. BIODESIX WORKSHOP: On November 12, at 4:00 ET, Dr. Gary Pestano, C ...

OPKO Health (NasdaqGS:OPK) Q3 2025 Earnings Call October 29, 2025 04:30 PM ET Speaker5Good afternoon and welcome to the OPKO Health third quarter 2025 financial results conference call. All participants will be in listen-only mode. Should you need assistance during the conference call, you may signal an operator by pressing star followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star, then one on your telephone keypad. To withdraw yo ...

BETHLEHEM, Pa., Oct. 29, 2025 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (NASDAQ: OSUR) has scheduled its regular earnings conference call covering third quarter 2025 financial results and certain business developments for 5 p.m. ET on November 5, 2025. A webcast of the conference call will be available on the investor relations page of OraSure’s website at https://orasure.gcs-web.com/events-and-presentations. Please click on the webcast link and follow the prompts for registration and access at least 1 ...

MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that it has launched the roadshow for its proposed initial public offering of 3,846,000 shares of its Class A common stock. In addition, BillionToOne intends to grant the underwriters a 30-day option to purchase up to an additional 576,900 shares of its Class A common stock at the initial public offering pri ...

(Catch all the US News, UK News, Canada News, International Breaking News Events, and Latest News Updates on The Economic Times.) Download The Economic Times News App to get Daily International News Updates. ...